Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Vanguard S&P 500 ETF — how do they compare? GSK plc trades at $50.44 (market cap $102.60B), while Vanguard S&P 500 ETF trades at $710.6. The key difference: GSK plc pays a 3.57% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.

GSKVOO
Market Cap
$102.60B
Sector
HealthBroad Market / Factor
52-Week High
$61.18$710.71
52-Week Low
$38.22$580.93
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Vanguard S&P 500 ETF

VOO trades at $710.69 with minimal daily movement (+0.01%), maintaining a bullish technical stance as the S&P 500 ETF approaches record highs. The overall technical signal is bullish with strong moving average support, though oscillators show neutral momentum. Recent news highlights the S&P 500's elevated valuation levels while institutional interest remains strong, with Bay Colony Advisory increasing its position by 8.6% in Q2 2026.

The ETF's outlook remains positive given its core exposure to large-cap US equities, but investors face valuation concerns with the S&P 500 trading at historically high multiples. Key risks include market volatility around inflation data and potential profit-taking near resistance levels, while institutional accumulation suggests continued confidence in the broader market trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.

Read more on VOO